EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

Candida Vitale iD, Thomas Chatzikonstantinou iD, Christina Papangelou, Francesca Perutelli iD, Maria Chiara Montalbano, Giulia Bondielli, Elia Boccellato iD, Salem Alshemmari iD, Francesco Angotzi, Miguel Arguello-Tomas iD, Tomas Arpas, Sandra Bašić-Kinda und 48 weitere

HemaSphere · 2026-11 · 10 (11)

DOI: 10.1002/hem3.70522 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HemaSphere, online erschienen am 06.11.2026. Verfasst von Candida Vitale und 59 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University …. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based combinations. In this retrospective multicenter study, data from 1720 patients were collected; 23.1% received venetoclax single agent and 76.9% venetoclax combinations (mostly containing anti‐CD20 monoclonal antibodies and/or BTK inhibitors). Combination regimens were used in 97.7% of treatment‐naïve (TN) patients and 65.8% of patients with relapsed/refractory (R/R) CLL. Preexisting AIC were reported in 11.7% of patients (8.7% in TN and 13.4% in R/R, P = 0.005). CLL‐related genetic risk factors and disease outcomes did not differ in patients with and without preexisting AIC. Irrespective of treatment type, venetoclax therapy resulted in AIC resolution or improvement in 63% of patients with active or controlled AIC. Treatment‐emergent AIC occurred in 2.6% of patients (2% in TN and 2.9% in R/R, not statistically significant). AIC episodes were reported in 4.3% of patients treated with venetoclax monotherapy and in 2.1% of those treated with venetoclax‐based combinations (P = 0.02). After standard management, AIC was considered resolved or controlled in 82% of the patients, with no substantial difference between treatment groups. Venetoclax‐based therapies have a beneficial impact on the outcome of CLL‐associated preexisting AIC. Treatment‐emergent AIC is a rare and generally manageable event. Although more frequent with venetoclax monotherapy in unadjusted analysis, this association was attenuated after adjustment for baseline prognostic factors.

Autor:innen und Institutionen

  • Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Torino Italy.
  • Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece.
  • Department of Hematology Santa Croce e Carle Hospital Cuneo Italy.
  • Department of Medicine, Faculty of Medicine Kuwait University Kuwait City Kuwait.
  • Hematology Unit, Department of Medicine University of Padova Padova Italy.
  • Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Departamento de Medicina Universidad Autónoma de Barcelona Barcelona Spain.

ORCID-Profile: Candida Vitale, Thomas Chatzikonstantinou, Francesca Perutelli, Elia Boccellato, Salem Alshemmari, Miguel Arguello-Tomas, Łukasz Bołkun, Tomasz Buczek, Aleksandra Butrym, Rosa Collado, Raul Cordoba Mascuñano, Lorenzo De Paoli, Marina Deodato, Maria Dimou, David Donaldson, Joanna Drozd-Sokołowska, Alberto Fresa, Anna Maria Frustaci, Ajay Gogia, Isabel González-Gascón-Y-Marín, Vasko Graklanov, Zhu Huayuan, Elzbieta Iskierka-Jażdżewska, Paula Jablonowska-Babij, Ozren Jaksic, Elzbieta Kalicińska, Maria Kislova, Maya Koren-Michowitz, Epameinondas Koumpis, Jorge Labrador, Shai Levi, Francesca Martini, Riccardo Moia, Roberta Murru, Ewa Paszkiewicz-Kozik, Alessandro Sanna

Zitieren

APA

Vitale, C., Chatzikonstantinou, T., Papangelou, C., Perutelli, F., Montalbano, M. C., Bondielli, G., Boccellato, E., Alshemmari, S., Angotzi, F., Arguello-Tomas, M., Arpas, T., Bašić-Kinda, S., Besikli-Dimou, S., Bołkun, Ł., Buczek, T., Butrym, A., Chapis, K., Chatzileontiadou, S., Collado, R., …, & Sanna, A. (2026). Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC. HemaSphere, 10(11). https://doi.org/10.1002/hem3.70522

Vancouver

Vitale C, Chatzikonstantinou T, Papangelou C, Perutelli F, Montalbano MC, Bondielli G, et al. Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC. HemaSphere. 2026;10(11). doi:10.1002/hem3.70522

BibTeX
@article{Vitale2026,
  author = {Vitale, Candida and Chatzikonstantinou, Thomas and Papangelou, Christina and Perutelli, Francesca and Montalbano, Maria Chiara and Bondielli, Giulia and Boccellato, Elia and Alshemmari, Salem and Angotzi, Francesco and Arguello-Tomas, Miguel and Arpas, Tomas and Bašić-Kinda, Sandra and Besikli-Dimou, Sotiria and Bołkun, Łukasz and Buczek, Tomasz and Butrym, Aleksandra and Chapis, Katherine and Chatzileontiadou, Sofia and Collado, Rosa and Cordoba Mascuñano, Raul and De Paoli, Lorenzo and Deodato, Marina and Dimou, Maria and Donaldson, David and Drozd-Sokołowska, Joanna and Elias, Salem and Ferrario, Andrea and Fresa, Alberto and Frustaci, Anna Maria and García-Serra, Rocío and Gogia, Ajay and González-Gascón-Y-Marín, Isabel and Graklanov, Vasko and Hryniewiecka, Maria and Huayuan, Zhu and Iskierka-Jażdżewska, Elzbieta and Jablonowska-Babij, Paula and Jaksic, Ozren and Kalicińska, Elzbieta and Kislova, Maria and Koren-Michowitz, Maya and Koumpis, Epameinondas and Kubová, Zuzana and Labrador, Jorge and Lauzzana, Pietro and Levi, Shai and Martini, Francesca and Mikhaleva, Mariia and Minga, Eva and Moia, Riccardo and Morawiec-Szymonik, Elżbieta and Morawska, Marta and Mulder, Femke V M and Murru, Roberta and Olivieri, Jacopo and Paszkiewicz-Kozik, Ewa and Rani, Lata and Roncero, Josep Maria and Salamon, Wojciech and Sanna, Alessandro},
  title = {Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC},
  journal = {HemaSphere},
  year = {2026},
  volume = {10},
  number = {11},
  doi = {10.1002/hem3.70522}
}
Kostenlos starten →